Trevi Therapeutics (TRVI) Current Assets (2018 - 2026)

Trevi Therapeutics' Current Assets history runs 9 years deep, the most recent figure standing at $176.1 million for Q1 2026.

• In Q1 2026, Current Assets rose 66.75% year-over-year to $176.1 million; the TTM figure through Mar 2026 stood at $176.1 million (up 66.75% YoY), while the FY2025 annual figure was $191.7 million, up 75.14% from the prior year.
• Current Assets for Q1 2026 stood at $176.1 million, down from $191.7 million in the prior quarter.
• The five-year high for Current Assets was $207.2 million in Q2 2025, with the low at $29.8 million in Q1 2022.
• The 5-year median for Current Assets is $105.6 million (2025), against an average of $115.2 million.
• The sharpest annual moves came in 2022 and 2024: Current Assets soared 314.62% in 2022, then plunged 32.78% in 2024.
• Trevi Therapeutics' Current Assets stood at $122.6 million in 2022, then slipped by 28.6% to $87.5 million in 2023, then rose by 24.99% to $109.4 million in 2024, then soared by 75.14% to $191.7 million in 2025, then dropped by 8.11% to $176.1 million in 2026.
• Business Quant data shows TRVI's Current Assets at $176.1 million in Q1 2026, $191.7 million in Q4 2025, and $198.3 million in Q3 2025.